

Long non-coding RNA MCM3AP-AS1 facilitates colorectal cancer progression by regulating the microRNA-599/ARPP19 axis

YOU YU, SUHE LAI and XIAOCHAO PENG

Department of General Surgery, The Bishan Hospital of Chongqing, Chongqing 402760, P.R. China

Received May 15, 2020; Accepted November 5, 2020

DOI: 10.3892/ol.2021.12486

Abstract. Colorectal cancer (CRC) is one of the most aggressive malignancies worldwide. Increasing evidence has indicated that microRNA (miR)-599 is involved in the occurrence and development of different types of tumors, such as breast cancer and glioma. However, the role of miR-599 in CRC remains unclear. Thus, the present study aimed to identify the regulatory mechanism of miR-599 in CRC progression. Reverse transcription-quantitative PCR was used to analyze the expression levels of MCM3AP-AS1, miR-599 and ARPP19, and Cell Counting Kit-8 and Transwell assays were used to determine the cell proliferation and migration of CRC cells. In addition, a Dual-luciferase reporter assay was used to analyze the direct interaction between miR-599 and MCM3AP-AS1 or ARPP19. Reverse transcription-quantitative PCR analysis demonstrated that miR-599 expression decreased in patients with CRC and in CRC cell lines, while miR-599 overexpression inhibited cell proliferation and migration abilities *in vitro*. MCM3AP-AS1 was identified as a molecular sponge of miR-599, and further investigation indicated that MCM3AP-AS1 silencing inhibited cell proliferation and migration of the CRC cell lines. In addition, ARPP19 was identified as a target gene of miR-599, and MCM3AP-AS1-knockdown decreased ARPP19 mRNA expression and increased miR-599 expression. Furthermore, silencing ARPP19 inhibited the proliferation and migration of the CRC cell lines. The results also demonstrated that MCM3AP-AS1 promoted CRC cell progression by regulating the miR-599/ARPP19 axis. Taken together, the results of the present study suggest that MCM3AP-AS1 may be a novel therapeutic target for patients with CRC.

Introduction

Colorectal cancer (CRC) is one of the most common malignancies with 1.4 million new cases and >690,000 associated mortalities in 2012 (1). Recent advancements in prognosis and therapeutic strategies in CRC have been made (2); however, due to metastasis and the fast-growing nature, the 5-year survival rate of patients with CRC remains poor, at only ~14% (3-5). Thus, it remains critical to develop novel reliable molecular markers for CRC treatment.

MicroRNAs (miRNAs/miRs) are small RNA molecules, 21-25 nucleotides in length, which have the ability to induce mRNA degradation or repress translation by binding to the 3'-untranslated region of RNA transcripts (6). It has been reported that dysregulated miRNAs are frequently involved in different types of human cancer, as both oncogenes and tumor suppressors. For example, overexpression of miR-187 inhibits cell proliferation and metastasis of glioma by down-regulating SMAD1 expression (7). miR-599 has been reported to act as a tumor suppressor in several types of cancer. For example, miR-599 suppresses glioma progression by targeting RAB27B (8). However, the regulatory mechanism of miR-599 in CRC remains unclear.

Long non-coding (lnc)RNAs are RNA molecules, >200 nucleotides in length, which are involved in different types of cellular processes, such as proliferation, migration and differentiation (9-13). Previous studies have demonstrated that lncRNAs are important regulatory factors that participate in cell proliferation, invasion and metastasis (14-16). For example, lncRNA RBM5-AS1 promotes the aggressive behaviors of oral squamous cell carcinoma by regulating the miR-1285-3p/YAP1 axis (17). A previous study also demonstrated that lncRNAs can regulate the progression of different types of cancer by sponging miRNAs. For example, lncRNA RBMS3-AS3 acts as a miR-4534 sponge to inhibit prostate cancer progression by upregulating VASH1 expression (18). lncRNA SNHG17 acts as a ceRNA of miR-324-3p to contribute the progression of osteosarcoma (19). MCM3AP-AS1 has been reported to be involved in several types of cancer. For example, Yang *et al* (20) demonstrated that the MCM3AP-AS1/miR-211/KLF5/AGGF1 axis regulates glioblastoma angiogenesis, while Li *et al* (21) reported that overexpression of lncRNA MCM3AP-AS1 promotes lung cancer progression via the miR-340-5p/KPNA4 axis. In addition, Yang *et al* (22) revealed that MCM3AP-AS1 sponges miR-138 by modulating FOXK1 expression to

Correspondence to: Dr Suhe Lai, Department of General Surgery, The Bishan Hospital of Chongqing, 9 Shuangxing Avenue, Chongqing 402760, P.R. China
E-mail: suhelai1021@163.com

Key words: MCM3AP-AS1, microRNA-599, colorectal cancer, ARPP19

promote pancreatic cancer cell proliferation and migration. However, the molecular mechanism of MCM3AP-AS1 in CRC remains largely unknown.

The present study investigated the effects and mechanisms of lncRNA MCM3AP-AS1 on the proliferation and migration of CRC cells.

Materials and methods

Patients and tissue samples. CRC tissues and adjacent normal tissues were collected from 30 patients (18 males and 12 females) with a median age of 56 years (range, 38-67 years) between January 2018 and January 2019 at The Bishan Hospital of Chongqing (Chongqing, China). Adjacent normal tissues of the patients were at least 1-cm away from the tumor tissues. The specimens were immediately preserved at -80°C following surgical resection. The present study was approved by the Ethics Committee of The Bishan Hospital of Chongqing and written informed consent was provided by all patients prior to the study start.

CRC cell lines. Human CRC cell lines (HCT-116, SW620, SW480 and LoVo), the normal colorectal cell line (NCM460), and 293T cells were purchased from the American Type Culture Collection. All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), at 37°C in a humidified atmosphere with 5% CO₂.

Cell transfection. Short hairpin (sh)RNAs targeting MCM3AP-AS1 (sh-MCM3AP-AS1; 10 nM; 5'-GCGCCU UCCCUCUAACCUUAA-3') and non-targeting scrambled negative control (sh-NC; 10 nM; 5'-GGCAAGAUGAACGUC UGAAAU-3'), and miR-599 mimics (10 nM; 5'-AGCAGC AUUGUACAGGGCUAUCA-3') and their NC (NC mimics; 10 nM; 5'-UGUAAACGUACGUUCGUACCGUGA-3') were all purchased from Shanghai GenePharma Co., Ltd. For MCM3AP-AS1 and ARPP19 overexpression, the full-length MCM3AP-AS1 and ARPP19 gene sequences were amplified and subcloned into the pcDNA3.1 vector (Invitrogen; Thermo Fisher Scientific, Inc.) to synthesize pcDNA3.1/MCM3AP-AS1 and pcDNA3.1/ARPP19, respectively. Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for all transfections, according to the manufacturer's instructions, and incubated at 37°C for 48 h. All functional experiments were performed 48 h post-transfection.

Reverse transcription-quantitative (RT-q)PCR. Total RNA was extracted from CRC tissues, adjacent normal tissues, HCT-116, SW620, SW480, LoVo and NCM460 cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and reverse transcribed into cDNA using the RT kit (cat. no. RR047A; Takara Biotechnology Co., Ltd.), according to the manufacturer's protocol. qPCR was subsequently performed using the SYBR-Green PCR Master Mix kit (cat. no. DRR041A; Takara Biotechnology Co., Ltd.) according to the manufacturer's protocol. The following thermocycling conditions were used for qPCR: Pre-denaturation at 95°C for 15 sec, denaturation at 94°C for 30 sec, annealing at 60°C for 20 sec and extension at

72°C for 40 sec for 40 cycles. The primers were designed as follows: MCM3AP-AS1 forward, 5'-CGATTTGGCGTTAAC TTATTGA-3'; and reverse, 5'-ATCATTACAGAACATAAT CAACAGGTA-3'; ARPP19 forward, 5'-ACTCATGCAGCG GAGCTCTAG-3'; and reverse, 5'-GTTTCAGAGATGAAGG TCCGAACA-3'; miR-599 forward, 5'-TCGGCAGGUUCA AGCCAGGGG-3'; and reverse, 5'-CACTCAACTGGTGTC GTGGA-3'; GAPDH forward, 5'-CGGAGTCAACGGATT TGGTCGTAT-3'; and reverse, 5'-AGCCTTCTCCATGGT GGTGAAGAC-3'; U6 forward, 5'-GCTTCGGCAGCACAT ATACTAAAAT-3'; and reverse, 5'-CGCTTCACGAATTTG CGTGTCAT-3'. GAPDH was used as an internal control for MCM3AP-AS1 and ARPP19, while U6 was used as an internal control for miR-599. Relative mRNA expression levels were quantified using the 2^{-ΔΔC_q} method (23).

Cell Counting Kit-8 (CCK-8) assay. Cell proliferation was assessed via the CCK-8 assay (Dojindo Molecular Technologies, Inc.). Briefly, HCT-116 and SW480 cells were seeded into 96-well plates at a density of 2x10⁴ cells/well. Following transfection for 48 h, CCK-8 reagent was added to the wells at 37°C for 2 h, according to the manufacturer's instructions and cell proliferation was subsequently analyzed at a wavelength of 450 nm, using a microplate reader (Thermo Fisher Scientific, Inc.).

Bioinformatic prediction and Dual-luciferase reporter assay. StarBase 2.0 (<http://starbase.sysu.edu.cn>) was used to predict the potential downstream targets of MCM3AP-AS1 and miR-599. To assess the binding ability between different RNAs, wild type or mutant fragments (MCM3AP-AS1 and ARPP19) were amplified and cloned into the pGL3 luciferase vector (Promega Corporation). The wild-type or mutant fragments were subsequently transfected into 293T cells (American Type Culture Collection), which had been co-transfected with miR-599 mimics or NC mimics. Transfection was performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Following incubation for 48 h at 37°C, a Dual-luciferase reporter system (Promega Corporation) was used to measure the luciferase gene activity. Firefly luciferase activity was normalized to that of *Renilla* luciferase.

Migration assay. The migration efficiency of the CRC cell lines was assessed via the Transwell assay. The transfected HCT-116 and SW480 cells were plated in the upper chamber at the density of 2x10⁵ cells per well in serum-free DMEM. DMEM supplemented with 10% FBS was plated in the lower chambers. Following incubation for 48 h at 37°C, the migratory cells were stained with 0.1% crystal violet for 20 min at room temperature and counted under a light microscope (magnification, x200; Olympus Corporation).

Statistical analysis. Statistical analysis was performed using SPSS v20.0 software (IBM Corp.). All experiments were performed in triplicate and data are presented as the mean ± standard deviation. Comparisons among multiple groups were performed using one-way ANOVA, followed by Tukey's post hoc test. Comparisons between CRC tissues and adjacent normal tissues were performed using a paired Student's t-test, while comparisons between the experimental




Figure 1. Decreased miR-599 expression affects the migratory ability of CRC cell lines. (A and B) Reverse transcription-quantitative PCR was used to assess miR-599 expression in the CRC tissues and cell lines (HCT-116, SW620, SW480 and LoVo) compared with that in adjacent normal tissues and NCM460 cell line. (C) Transfection with miR-599 mimics upregulated miR-599 expression in HCT-116 and SW480 cells. (D) Cell Counting Kit-8 assay was performed to assess cell proliferation following overexpression of miR-599. (E) Transwell assay (magnification, x200) was performed to assess the migratory ability of the CRC cell lines following overexpression of miR-599. * $P < 0.05$ vs. NC mimics. miR, microRNA; CRC, colorectal cancer; NC, negative control; OD, optical density.

and control groups was performed using an unpaired Student's *t*-test. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Decreased miR-599 expression affects the migratory ability of CRC cell lines. The results demonstrated that miR-599 expression was significantly decreased in the CRC tissues and cell lines (HCT-116, SW620, SW480 and LoVo) compared with that in adjacent normal tissues and the NCM460 cell line (Fig. 1A and B). Especially, miR-599 expression was significantly higher in HCT-116 and SW480 cells, compared with NCM460 cells. Thus, HCT-116 and SW480 cells were selected to perform subsequent experiments. RT-qPCR analysis

demonstrated that transfection with miR-599 mimics significantly enhanced miR-599 expression in HCT-116 and SW480 cells (Fig. 1C). Furthermore, the results from the CCK-8 assay indicated that overexpression of miR-599 significantly inhibited cell proliferation (Fig. 1D), while the results from the Transwell assay demonstrated that miR-599 overexpression significantly decreased the migratory ability of the CRC cell lines (Fig. 1E). Collectively, these results suggest that miR-599 has an antitumor effect on CRC cell lines.

MCM3AP-AS1 sponges miR-599 to accelerate CRC progression. lncRNAs exert their functions by interacting with downstream target miRNAs (24). In the present study, a potential target site between miR-599 and MCM3AP-AS1 was predicted using StarBase software (Fig. 2A). A Dual-luciferase




Figure 2. MCM3AP-AS1 sponges miR-599 to accelerate CRC progression. (A) Binding sequences between MCM3AP-AS1 and miR-599 were predicted using StarBase software. (B) Dual-luciferase reporter assay was used to verify the binding ability between MCM3AP-AS1 and miR-599 in 293T cells. (C) RT-qPCR analysis was performed to detect MCM3AP-AS1 expression in the CRC cell lines and normal NCM460 cell line. (D) RT-qPCR analysis demonstrated that MCM3AP-AS1 expression decreased following transfection with sh-MCM3AP-AS1 in HCT-116 and SW480 cells. (E) RT-qPCR analysis was performed to detect miR-599 expression following transfection with sh-MCM3AP-AS1 in HCT-116 and SW480 cells. (F) Cell Counting Kit-8 and (G) Transwell assays (magnification, x200) were performed to detect cell proliferation and migration following MCM3AP-AS1-knockdown, respectively. * $P < 0.05$ vs. shNC. miR, microRNA; CRC, colorectal cancer; RT-qPCR, reverse transcription-quantitative PCR; sh, short hairpin; NC, negative control; WT, wild-type; MUT, mutant; OD, optical density.

reporter assay was performed for validation, and the results demonstrated that transfection with miR-599 mimics significantly suppressed the luciferase activity of wild-type MCM3AP-AS1; however, no effect was observed on mutant MCM3AP-AS1 (Fig. 2B). In addition, MCM3AP-AS1 mRNA expression was significantly elevated in the CRC cell lines compared with that in the NCM460 cell line (Fig. 2C).

To further investigate the biological function of MCM3AP-AS1 in CRC, HCT-116 and SW480 cells were transfected with sh-MCM3AP-AS1 or sh-NC. RT-qPCR analysis confirmed that MCM3AP-AS1 mRNA expression significantly decreased with sh-MCM3AP-AS1 transfection (Fig. 2D). In addition, miR-599 expression significantly increased in HCT-116

and SW480 cells following MCM3AP-AS1-knockdown (Fig. 2E). The results from the CCK-8 and Transwell assays demonstrated that MCM3AP-AS1-knockdown significantly attenuated cell proliferation and migration, respectively (Fig. 2F and G). Taken together, these results suggest that MCM3AP-AS1 acts as a sponge of miR-599, and is involved in CRC.

MCM3AP-AS1 interacts with miR-599 to regulate ARPP19 in CRC. Previous studies have demonstrated that lncRNAs exert their functions by sponging miRNAs to regulate mRNAs (25-27). The StarBase software predicted that ARPP19 was a direct target of miR-599 (Fig. 3A), and RT-qPCR analysis




Figure 3. MCM3AP-AS1 interacts with miR-599 to regulate ARPP19 in colorectal cancer. (A) The binding sites between ARPP19 and miR-599. (B) RT-qPCR analysis demonstrated that ARPP19 expression was significantly increased in SW480 cells compared with that in normal NCM460 cells. (C) RT-qPCR analysis was performed to detect ARPP19 expression in SW480 cells following overexpression of miR-599 and MCM3AP-AS1-knockdown, respectively. (D) RT-qPCR analysis was performed to detect MCM3AP-AS1 expression in SW480 cells following transfection with pcDNA3.1/MCM3AP-AS1. (E) Dual-luciferase reporter assay validated the interaction between ARPP19 and miR-599, following overexpression of MCM3AP-AS1. * $P < 0.05$ vs. NC mimics. miR, microRNA; RT-qPCR, reverse transcription-quantitative PCR; sh, short hairpin; NC, negative control; WT, wild-type; MUT, mutant.

demonstrated that ARPP19 mRNA expression increased in SW480 cells compared with that in normal NCM460 cells (Fig. 3B). In addition, transfection with sh-MCM3AP-AS1 or miR-599 mimics significantly decreased ARPP19 mRNA expression in SW480 cells (Fig. 3C). Notably, MCM3AP-AS1 expression was significantly enhanced in SW480 cells following transfection with pcDNA3.1/MCM3AP-AS1 (Fig. 3D). Furthermore, inhibition of miR-599 mimics based on luciferase activity in wild-type ARPP19 was decreased following overexpression of MCM3AP-AS1, while there was no change in luciferase activity in mutant ARPP19 (Fig. 3E). Collectively, these results suggest that MCM3AP-AS1 regulates ARPP19 by modulating miR-599 in CRC.

MCM3AP-AS1 accelerates CRC progression via the miR-599/ARPP19 axis. To determine whether MCM3AP-AS1 promoted CRC progression via the miR-599/ARPP19 axis, a series of rescue experiments were performed. The results demonstrated that ARPP19 mRNA expression significantly decreased following transfection with sh-ARPP19 in SW480 cells (Fig. 4A). In addition, SW480 cell proliferation and migration were attenuated following ARPP19-knockdown, respectively (Fig. 4B and C). SW480 cells were transfected with pcDNA3.1, pcDNA3.1/MCM3AP-AS1 and pcDNA3.1/MCM3AP-AS1+miR-599, and the results

demonstrated that MCM3AP-AS1 and ARPP19 expression levels increased following overexpression of MCM3AP-AS1, the effects of which were partially reversed following transfection with the miR-599 mimic (Fig. 4D and E). In addition, miR-599 expression decreased following overexpression of MCM3AP-AS1, the effect of which was partially reversed following transfection with the miR-599 mimic (Fig. 4F). The results from the CCK-8 and Transwell assays demonstrated that overexpression of MCM3AP-AS1 promoted SW480 cell proliferation and migration, respectively, the effects of which were partially reversed following overexpression of miR-599 (Fig. 4G and H). Taken together, these results suggest that MCM3AP-AS1 sponges miR-599 and increases ARPP19 mRNA expression to accelerate CRC progression.

Discussion

Increasing evidence has indicated that miRNAs may have an antitumor role in different types of tumor. For example, miR-192 has been demonstrated to inhibit the progression of lung cancer bone metastasis by regulating TRIM44 (28). miR-506-3p inhibits papillary thyroid cancer cells tumorigenesis via targeting YAP1 (29). miR-296-5p suppresses the tumorigenesis of esophageal squamous cell carcinoma cells via inhibiting STAT3 signaling (30). The present study




Figure 4. MCM3AP-AS1 accelerates colorectal cancer progression via the miR-599/ARPP19 axis. (A) RT-qPCR analysis was performed to detect ARPP19 expression in SW480 cells following ARPP19-knockdown. (B) CCK-8 and (C) Transwell assays (magnification, x200) were performed to assess the proliferation and migration of SW480 cells following ARPP19-knockdown, respectively. RT-qPCR analysis was performed to detect (D) MCM3AP-AS1, (E) ARPP19 and (F) miR-599 expression levels in SW480 cells transfected with pcDNA3.1, pcDNA3.1/MCM3AP-AS1 and pcDNA3.1/MCM3AP-AS1+miR-599. (G) CCK-8 and (H) Transwell assays (magnification, x200) were performed to assess the proliferation and migration of SW480 cells transfected with pcDNA3.1, pcDNA3.1/MCM3AP-AS1 and pcDNA3.1/MCM3AP-AS1+miR-599, respectively. * $P < 0.05$ vs. pcDNA3.1. miR, microRNA; RT-qPCR, reverse transcription-quantitative PCR; CCK-8, Cell Counting Kit-8; sh, short hairpin; NC, negative control; OD, optical density.

demonstrated that miR-599 was involved in CRC, whereby its expression was decreased in the examined CRC cell lines. In addition, overexpression of miR-599 inhibited cell proliferation and migration in CRC.

lncRNAs have been reported to act as competing endogenous (ce)RNAs that sponge miRNAs. For example, lncRNA FAL1 acts as a ceRNA of miR-1236 to promote cell proliferation and migration in hepatocellular carcinoma (HCC) (31), while lncRNA-UCA1 acts as a ceRNA of Sox4 to promote cell proliferation in esophageal cancer (32). In the present study, MCM3AP-AS1 was demonstrated to negatively regulate miR-599 via direct interaction. Notably, MCM3AP-AS1 has been reported to participate in the progression of different types of cancer. For example, Liang *et al.* (33) demonstrated that MCM3AP-AS1 promotes proliferation and invasion in papillary thyroid cancer by regulating the miR-211-5p/SPARC axis. In addition, Wang *et al.* (34) reported that MCM3AP-AS1 promotes HCC progression by regulating the miR-194-5p/FOXA1 axis. However, the molecular mechanism of MCM3AP-AS1 in CRC remains unclear. The results from the present study demonstrated that MCM3AP-AS1 sponged miR-599 to accelerate CRC progression. In addition, MCM3AP-AS1 mRNA expression was increased in the CRC cell lines. *In vitro* functional assays were performed and the results demonstrated that MCM3AP-AS1-knockdown significantly decreased the proliferation and migration of CRC cells. Collectively, the results of the present study demonstrated that

MCM3AP-AS1 accelerated CRC progression by binding to miR-599.

Previous studies have reported that miRNAs are involved in tumor progression by targeting mRNAs. For example, miR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19 (35). In addition, miR-9-5p targets GOT1 to inhibit pancreatic cancer cell proliferation, invasion and metabolism (36). In the present study, bioinformatics analysis and the Dual-luciferase reporter assay confirmed that miR-599 directly binds to ARPP19. Furthermore, MCM3AP-AS1-knockdown decreased ARPP19 mRNA expression by promoting miR-599 expression. The results also demonstrated that ARPP19-knockdown attenuated the proliferation and migration of CRC cells. In addition, overexpression of MCM3AP-AS1 increased ARPP19 mRNA expression, the effect of which was reversed following transfection with miR-599 mimics. Notably, MCM3AP-AS1 promoted CRC progression via the miR-599/ARPP19 axis.

In conclusion, the results of the present study suggest that lncRNA MCM3AP-AS1 exerts its biological functions by modulating the miR-599/ARPP19 axis, thus MCM3AP-AS1 may be an effective therapeutic target for CRC. However, the current study is limited by the small sample size. Besides, *in vivo* interactions among MCM3AP-AS1, miR-599 and ARPP19 have not been explored. Future research is required to include *in vivo* experiments and enroll more patients to further verify these conclusions.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YY designed the study. YY, SL and XP performed the research and analyzed the data. XP and YY wrote the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

The protocol of this research has been approved by the Ethics Committee of The Bishan Hospital of Chongqing (Chongqing, China; approval no. 2017A110502) and written informed consent was provided by all patients prior to the start of the study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. *CA Cancer J Clin* 65: 87-108, 2015.
2. Chen X, Zeng K, Xu M, Hu X, Liu X, Xu T, He B, Pan Y, Sun H and Wang S: SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. *Cell death & disease* 9: 1-18, 2018.
3. Ahmed S, Johnson K, Ahmed O and Iqbal N: Advances in the management of colorectal cancer: From biology to treatment. *Int J Colorectal Dis* 29: 1031-1042, 2014.
4. Mele V, Sokol L, Kölzer VH, Pfaff D, Muraro MG, Keller I, Stefan Z, Centeno I, Terracciano LM, Dawson H, *et al*: The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. *Oncotarget* 8: 70617-70629, 2017.
5. Yang KM, Park JJ, Lee JL, Kim CW, Yoon YS, Lim SB, Yu CS and Kim JC: Benefits of repeated resections for liver and lung metastases from colorectal cancer. *Asian J Surg* 43: 102-109, 2020.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.
7. Gulinaer AJ, Ju AN, Gao M, Luo Y and Bo YL: Over-expression of miR-187 inhibited cell proliferation and metastasis of glioma via down-regulating SMAD1. *Eur Rev Med Pharmacol Sci* 23: 10908-10917, 2019.
8. Jiang Y, Wang X, Zhang J and Lai R: MicroRNA-599 suppresses glioma progression by targeting RAB27B. *Oncol Lett* 16: 1243-1252, 2018.
9. Sheng XY, Wang CH, Wang CF and Xu HY: Long-chain non-coding SOX21-AS1 promotes proliferation and migration of breast cancer cells through the PI3K/AKT signaling pathway. *Cancer Manag Res* 12: 11005-11014, 2020.
10. Tang G, Luo L, Zhang J, Zhai D, Huang D, Yin J, Zhou Q, Zhang Q and Zheng G: lncRNA LINC01057 promotes mesenchymal differentiation by activating NF-KB signaling in glioblastoma. *Cancer Lett*, October 31, 2020 (Online ahead of print).
11. Liu Y, Yang Y, Li L, Liu Y, Geng P, Li G and Song H: lncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. *Biochem Cell Biol* 96: 38-43, 2018.
12. Batista PJ and Chang HY: Long noncoding RNAs: Cellular address codes in development and disease. *Cell* 152: 1298-1307, 2013.
13. Yang L, Froberg JE and Lee JT: Long noncoding RNAs: Fresh perspectives into the RNA world. *Trends Biochem Sci* 39: 35-43, 2014.
14. Zhang H, Bai M, Zeng A, Si L, Yu N and Wang X: lncRNA HOXD-AS1 promotes melanoma cell proliferation and invasion by suppressing RUNX3 expression. *Am J Cancer Res* 7: 2526-2535, 2017.
15. Lian Y, Cai Z, Gong H, Xue S, Wu D and Wang K: HOTTIP: A critical oncogenic long non-coding RNA in human cancers. *Mol Biosyst* 12: 3247-3253, 2016.
16. Lv M, Zhong Z, Huang M, Tian Q, Jiang R and Chen J: lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. *Biochim Biophys Acta Mol Cell Res* 1864: 1887-1899, 2017.
17. Li C, Ye J, Zhang Z, Gong Z, Lin Z and Ding M: Long non-coding RNA RBM5-AS1 promotes the aggressive behaviors of oral squamous cell carcinoma by regulation of miR-1285-3p/YAP1 axis. *Biomed Pharmacother* 123: 109723, 2019.
18. Jiang Z, Zhang Y, Chen X, Wu P and Chen D: Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1. *Gene Ther* 27: 143-156, 2020.
19. Zhang YT and Yang GY: lncRNA SNHG17 acts as a ceRNA of miR-324-3p to contribute the progression of osteosarcoma. *J Biol Regul Homeost Agents* 34: 1529-1533, 2020.
20. Yang C, Zheng J, Xue Y, Yu H, Liu X, Ma J, Liu L, Wang P, Li Z, Cai H and Liu Y: The effect of MCM3AP-AS1/miR-211/KLF5/AGGF1 axis regulating glioblastoma angiogenesis. *Front Mol Neurosci* 10: 437, 2018.
21. Li X, Yu M and Yang C: YY1-mediated overexpression of long noncoding RNA MCM3AP-AS1 accelerates angiogenesis and progression in lung cancer by targeting miR-340-5p/KPNA4 axis. *J Cell Biochem* 121: 2258-2267, 2020.
22. Yang M, Sun S, Guo Y, Qin J and Liu G: Long non-coding RNA MCM3AP-AS1 promotes growth and migration through modulating FOXK1 by sponging miR-138-5p in pancreatic cancer. *Mol Med* 25: 55, 2019.
23. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
24. Paraskevopoulou MD and Hatzigeorgiou AG: Analyzing MiRNA-lncRNA interactions. *Methods Mol Biol* 1402: 271-286, 2016.
25. Liu Z, Li Z, Xu B, Yao H, Qi S and Tai J: Long noncoding RNA PRR34-AS1 aggravates the progression of hepatocellular carcinoma by adsorbing microRNA-498 and thereby upregulating FOXO3. *Cancer Manag Res* 12: 10749-10762, 2020.
26. Wang S, Wang T, Liu D and Kong H: lncRNA MALAT1 aggravates the progression of non-small cell lung cancer by stimulating the expression of COMMD8 via targeting miR-613. *Cancer Manag Res* 12: 10735-10747, 2020.
27. Zhou Y, Shi H, Du Y, Zhao G, Wang X, Li Q, Liu J, Ye L, Shen Z, Guo Y and Huang Y: lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis. *Aging (Albany NY)* 11: 7386-7401, 2019.
28. Zou P, Zhu M, Lian C, Wang J, Chen Z, Zhang X, Yang Y, Chen X, Cui X, Liu J, *et al*: miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44. *Sci Rep* 9: 19619, 2019.
29. Chen L, Wang X, Ji C, Hu J and Fang L: MiR-506-3p suppresses papillary thyroid cancer cells tumorigenesis by targeting YAP1. *Pathol Res Pract* 216: 153231, 2020.

30. Wang ZZ, Luo YR, Du J, Yu Y, Yang XZ, Cui YJ and Jin XF: MiR-296-5p inhibits cell invasion and migration of esophageal squamous cell carcinoma by downregulating STAT3 signaling. *Eur Rev Med Pharmacol Sci* 23: 5206-5214, 2019.
31. Li B, Mao R, Liu C, Zhang W, Tang Y and Guo Z: LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells. *Life Sci* 197: 122-129, 2018.
32. Jiao C, Song Z, Chen J, Zhong J, Cai W, Tian S, Chen S, Yi Y and Xiao Y: lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. *Oncol Rep* 36: 2960-2966, 2016.
33. Liang M, Jia J, Chen L, Wei B, Guan Q, Ding Z, Yu J, Pang R and He G: LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer. *Endocrine* 65: 318-326, 2019.
34. Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, Tong X, Yang W, Xu Q, Huang D and Tu K: A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. *Mol Cancer* 18: 28, 2019.
35. Gong Y, Wu W, Zou X, Liu F, Wei T and Zhu J: MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19. *Am J Cancer Res* 8: 1030-1039, 2018.
36. Wang J, Wang B, Ren H and Chen W: miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting GOT1. *Biochem Biophys Res Commun* 509: 241-248, 2019.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.